SGP
SpyGlass Pharma, Inc.
Next earnings ≈ Jul 2, 2026 · est. from filing cadence
Last earnings +1.9% on 2026-05-14
$21.18
▲ +12.60%$21.18▼ -19.77%
over 1Y
L $17.56EODHDH $29.68
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+12.6%
1W+9.5%
1M+5.0%
3M-6.3%
YTD-19.8%
1Y-19.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Strong Buy
Conservative balance sheet (liabilities/equity -0.10x).
SpyGlass Pharma, Inc. shows limited reported revenue.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$27.1M | -$41.4M |
| Net income | -$29.2M | -$39.9M |
| Diluted EPS | -$16.31 | -$17.98 |
| Net margin | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$612M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-5.6%
FCF yield-4.7%
Quality & risk
ROIC (est.)—
Free cash flow-$33.5M
Total debt—
Net cash$96.4M
Capital returns
Buyback yield0.2%
Dividend yield (est.)—
Shareholder yield0.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-KPeriod ending 2025-12-312026-03-26open ↗8-KPeriod ending 2026-03-262026-03-26open ↗8-KPeriod ending 2026-03-092026-03-09open ↗SCHEDULE 13GFiling2026-02-17open ↗SCHEDULE 13DFiling2026-02-17open ↗SCHEDULE 13DFiling2026-02-13open ↗SCHEDULE 13DFiling2026-02-13open ↗8-KPeriod ending 2026-02-122026-02-13open ↗SCHEDULE 13GFiling2026-02-13open ↗4Period ending 2026-02-092026-02-11open ↗
Frequently asked
- Is SpyGlass Pharma, Inc. (SGP) a buy?
- SGP currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -0.10x).
- What is SpyGlass Pharma, Inc.'s quality score?
- SGP scores 18.999999999999996/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001778922, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:53:10 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.